By Vincent Joralemon As therapies using drugs like MDMA, psilocybin, and LSD advance through the FDA research and approval pipeline, patients should be prepared for steep price tags attached to these procedures. For example, experts estimate MDMA-assisted therapy for PTSD will cost upwards of $12,000 per patient. These high costs highlight the need for comprehensive…
Not all lobbying campaigns are problematic — the goal should be for regulators to leverage industry insights while maintaining independence in decision-making.
As we move past a phase of “partial eclipse” by psychedelic hype, this critical field is finally well-situated to explore the full spectrum of psychedelic effects.
There is little consensus in defining “psychedelic.” Yet, research on and access to these substances hinges on what gets included under this umbrella.
A combination of high demand and a patent monopoly has created a perfect storm of profitability for Janssen’s Spravato.
The most effective way to change peoples’ opinions is to highlight the success stories of those who have tried psychedelics.
A spate of recent exposés have detailed the proliferation of abuse in psychedelic therapy, underscoring the urgent need for ethical guidance.
